Immunization recommendations in children with acute lymphoblastic leukemia.

Area of Science:

• Pediatric Oncology
• Immunology
• Public Health

Background:

• Cancer is the leading cause of death in Mexican children aged 5-14, with acute leukemia being the most common malignancy.
• Vaccination is crucial for these children but often challenging during intensive treatment periods.
• Understanding vaccine types and their administration during chemotherapy is vital for improving survival rates.

Purpose of the Study:

• To review available vaccines in Mexico for children with acute lymphoblastic leukemia (ALL).
• To assess the scientific evidence on the safety and efficacy of different vaccine types during and after oncological treatment.
• To determine optimal vaccination timing for pediatric ALL patients undergoing chemotherapy.

Main Methods:

• A comprehensive review of vaccines available in Mexico was conducted.
• Scientific literature on vaccine safety and efficacy in pediatric oncology patients was analyzed.
• Guidelines for vaccine administration during and after chemotherapy for acute lymphoblastic leukemia were evaluated.

Main Results:

• Non-live vaccines (toxoids, protein subunits, bacterial antigens, recombinant proteins) are not contraindicated during chemotherapy for ALL.
• The review identified specific vaccine indications and evidence for their use in this patient population.
• Optimal timing for vaccine administration during and post-treatment was considered.

Conclusions:

• Non-live vaccines can be safely administered to children with acute lymphoblastic leukemia during chemotherapy.
• Evidence-based recommendations on vaccine selection and timing are essential for pediatric cancer care.
• This review provides valuable information for healthcare providers managing vaccine programs for pediatric ALL survivors in Mexico.